Swiss Gondola Medical Technologies Announces Collaboration with New York’s Mount Sinai Health System to Study Innovative Treatment for Neurological Disorders Such as Parkinson’s Disease
- Automated Peripheral Mechanical Stimulation improves patient mobility
- Non-invasive mechanical device stimulates nerves in patients’ feet
- Custom-fitted “boots” ensure contact points alignment
- Device is internationally patented and CE-marked
Epalinges, Switzerland, November 03, 2021 – Gondola Medical Technologies, a Swiss developer and marketer of a medical device to treat Parkinson’s disease, today announced a collaboration with New York’s Mount Sinai Health System to further study Automated Peripheral Mechanical Stimulation (APMS) therapy, upon which the Gondola device is based. The collaboration’s goal is to enhance the scientific understanding of AMPS theory by conducting additional clinical research on AMPS and its underlying mechanism of action.
Gondola’s internationally patented and CE- marked device provides non-invasive mechanical stimulation of two major nerves running from the soles of the feet to the deep brain. Small probes provide a rhythmic “massage’ of the nerve ends and custom-fitted “boots” for each patient ensure accurate contact points alignment. The treatment has demonstrated improved walking and gait for those impaired by neurological disorders.
The agreement includes Mount Sinai’s Abilities Research Center (ARC), part of the Department of of Rehabilitation and Human Performance. The research collaborators include David Putrino, Ph.D., PT, and Mar Cortes, MD, both co-Directors of the ARC; and Gabriela Rozanski, Ph.D., PT, a physical therapist and research professional. These clinicians and researchers are recognized leaders in investigating and implementing innovative technologies to empower individuals with neurological disorders to improve independence, mobility, and quality of life.
Commenting on the collaboration, Gondola’s CEO and Founder Francesco Cecchini said, “We are delighted and honored to engage with Mount Sinai and their prestigious team of experienced scientists and researchers in what we believe is a highly innovative approach to improving the quality of life for those suffering from neurological disorders, including Parkinson’s.”
About the study
The research team will measure reflex activity, electromyographic signals, intracortical inhibition, and motor-evoked potentials to provide information about which parts of the central and peripheral nervous system are activated or affected by the therapy. Measurements will be taken immediately after a first AMPS therapy session and after weeks to months of therapy to assess both short- and long-term effects on the nervous system. These results can be coupled with movement analyses, clinical outcomes, and functional measures to understand how AMPS can improve walking, independence, and quality of life for those suffering from neurological conditions.
About Gondola AMPS Therapy
The Gondola AMPS therapy works with mechanical pressure pulses applied in two specific areas of both feet, the head of the big toe and the first metatarsal joint. It is a two-minute therapy with instant results that is documented in 12 scientific publications with more than 230 Parkinson’s disease patients. Gondola AMPS treatment’s documented benefits provide significant improvements in walking abilities for speed, stride length, gait variability, and turning. Beneficial effects are apparent immediately after a single AMPS therapy and can remain on average two to four days.
About Mount Sinai Health System
The Mount Sinai Health System is an integrated health care system providing exceptional medical care to local and global communities. Mount Sinai is internationally recognized for its excellence in research, patient care, and education across a range of specialties. The Mount Sinai Health System was created from the combination of the Mount Sinai Medical Center and Continuum Health Partners, which both agreed unanimously to combine the two entities in July 2013. It is poised to identify and respond to the health-related needs of the diverse populations being served.
About Gondola Medical Technologies
Gondola Medical Technologies is a Swiss medical technology company based at Biopôle in the Canton of Vaud, Switzerland. As a therapeutic company it strives to make the Gondola AMPS therapy standard of care in treating walking and balance impairments due to neurological disorders. The Gondola Therapeutic Device is internationally patented and CE- marked.
###
Media Contacts:
Switzerland
Benjamin Duband
Head of Marketing & Communications
Gondola Medical Technologies
b.duband@gondola-medical.com
Mobile: +41 78 911 24 74
Gondola headquarters: +41 91 921 38 38
Lysine Building, Biopôle
Route de la Corniche 4
1066 Epalinges – Switzerland
US:
Ted Agne
The Communications Strategy Group Inc.
edagne@comstratgroup.com
+1 781 888 0099